InnoCom Bio Equities' investment fund offers a unique opportunity to contribute to critical medical advancements, with a portfolio of thirteen companies that have invested over $165 million in solutions for cancer, COVID-19, and more. The fund is projected to deliver substantial returns, with outside experts estimating a six-year valuation of $350 billion. The fund's risk is mitigated by its diversity, hands-on strategic and operational care, and an early commercialization strategy bolstered by strong ties with the veterinary community.
Deal activity and portfolio updates would appear here
Connect your data source to see recent transactions